The mammalian target of rapamycin
Introduction
Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer, and its incidence is increasing worldwide because of the dissemination of hepatitis B and C virus infections. The overall prognosis for patients with HCC is dismal with few effective treatment options (1) . Understanding the pathways involved in hepatocarcinogenesis is of particular interest because these factors may represent novel therapeutic targets for the treatment of patients with chronic liver diseases that predispose them to development of HCC. Specific signaling pathways, such as p53, Wnt/h-catenin, phosphatase and tensin homologue (PTEN)/ phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR), and the telomerase immortalization enzyme, are frequently dysregulated in HCC (2, 3) . The pathway of relevance to this study is the PTEN/PI3K/Akt/mTOR pathway. In mice, hepatocyte-specific PTEN deficiency results in HCCs (4) . In other organs, tumor formation resulting from PTEN ablation is suppressed by treatment of the mice with the rapamycin derivative CCI-779, a specific inhibitor of the mTOR kinase (5, 6) . The ability of rapamycin to suppress tumor formation in PTENdeficient mice has been attributed to the mTOR dependence of PI3K signaling. mTOR stimulates protein translation through phosphorylation of 4E-BP1 and p70 S6 kinase (7, 8) . Overexpression of the activated phosphorylated form of mTOR was observed in 15% of human HCCs and increased expression of p70 S6 kinase was found in 45% of cases and positively correlated with tumor size (9) . The aim of this study was to examine the role of activated mTOR in mediating the behavior of hepatocytic cells during neoplastic transformation.
The HepaRG cell line has been established from the nontumoral region of a resected HCV-associated HCC. These cells display bipotent differentiation-inducible properties and share some features with liver progenitor cells (10) . Throughout differentiation, HepaRG cells evolve from a homogeneous, dedifferentiated, depolarized, epithelial phenotype showing no specific organization to a well structurally defined and polarized monolayer closely resembling those formed in primary human hepatocyte culture, with bright canaliculi-like structures (10) . At the hepatocytic differentiated state, hepatocytic polarization markers such as ZO-1 and CD26 and liver-specific proteins such as albumin and transferrin, the glycolytic enzyme aldolase B, and enzymes involved in detoxification (CYP2E1, CYP3A4, and glutathione S-transferase a) are expressed at levels similar to those found in normal liver biopsies (10, 11) . Finally, iron storage and metabolism, typical features of mature hepatocytes, never observed in HCC, remain intact in HepaRG cells (12) . Although HepaRG cells do bear chromosomal aberrations (11) and cannot be considered normal liver parenchymal cells with differentiation-inducible properties, they constitute a powerful model for studying the role of specific pathways on hepatocytic differentiation and for evaluating the consequences of their dysregulation on hepatocarcinogenesis.
Materials and Methods
Cell culture and generation of #TOR and control HepaRG clones. The HepaRG cell line was cultured in William's E medium (Invitrogen) supplemented with 10% FCS (Cellgro), 100 units/mL penicillin, 100 Ag/mL streptomycin (Invitrogen), 5 Ag/mL insulin (Sigma), and 5 Â 10 À5 mol/L hydrocortisone hemisuccinate (Sigma). To generate DTOR and control HepaRG clones, 2 Â 10 6 cells were transfected with 2 Ag of pCDNA3 plasmid (Invitrogen), bearing or not the DTOR insert (provided by Dr. Edinger), using Lipofectamine 2000 (Invitrogen). After 24 h, 600 Ag/mL G418 (Invitrogen) was added to the culture medium, allowing selection of G418-resistant clones.
To induce differentiation, a two-step procedure was used as previously described (10) . Cells were seeded at a density of 4 Â 10 4 /cm 2 and maintained for 2 weeks in the growth medium. Then, the culture medium was supplemented with 1% DMSO (Sigma) and 20 ng/mL epidermal growth factor (Peprotech) for 2 additional weeks. For reversion experiments, rapamycin (2 ng/mL) was added from day 3 postseeding until the end of the differentiation process. For transforming growth factor-h (TGF-h) treatment, cells were seeded at a density of 10 4 /cm 2 . After 24 h, TGF-h (Peprotech) was added at a concentration of 2.5 ng/mL in medium supplemented with 0.5% FCS. After 72 h, cells were analyzed with a FACScan analyzer equipped with the Cell Quest software (Becton Dickinson). Cell culture pictures were taken using a phase-contrast microscope (Nikon) equipped with the Metamorph software. Differentiation was evaluated morphologically by counting bile canaliculi (refringent area) at the intersection of two or three hepatocyte-like cells (10) .
Western blotting and ELISA. Cells were lysed in 50 mmol/L Tris-HCl (pH 8), 150 mmol/L NaCl, 0.1% SDS, 1% NP40, supplemented with protease inhibitors (Complete, Roche). Twenty micrograms of proteins were resolved on 5%, 10%, or 15% SDS-polyacrylamide gels and electrotransferred onto nitrocellulose membrane (Amersham Biosciences). Equal loadings and homogeneous blotting were confirmed by Ponceau red staining. Membranes were blocked with 5% nonfat milk in TBS and incubated with primary antibodies overnight. The following antibodies were used: anti-phosphoAkt, anti-Akt, anti-phospho-mTOR, anti-mTOR, anti-4E-BP1, anti-p70 S6 kinase (Cell Signaling Technologies; dilution, 1/2,000); anti-AU1 tag (Babco; dilution, 1/2,000); anti-p21 (WAF1/CIP1) (PharMingen; dilution, 1/2,000). Horseradish peroxidase-conjugated immunoglobulins (Dako) were used as secondary antibodies and proteins were visualized with enhanced chemiluminescence reagent (Amersham Biosciences). a1-Antitrypsin quantitation in the supernatant was done using an ELISA with an a1-antitrypsin capture antibody (Antibody Shop), a rabbit anti-a1-antitrypsin detection antibody (Dako), and a donkey anti-rabbit immunoglobulin-horseradish peroxidase conjugate (Jackson ImmunoResearch).
Reverse transcription-PCR. One microgram of DNase I-treated (Promega) total RNA was reverse transcribed using Moloney murine leukemia virus reverse transcriptase and random hexamers (Invitrogen) for 50 min at 42jC. Primers for cyclin D1 and actin were 5 ¶-GGATGCTGG-AGGTCTGCGA-3 ¶ and 5 ¶-AGAGGCCACGAACATGCAAG-3 ¶, 5 ¶-TGGACTTC-GAGCAAGAGATGG-3 ¶ and 5 ¶-GGAAGGAAGGCTGGAAGAGTG-3 ¶, respectively. PCR cycle numbers for cyclin D1 and actin were 35 and 23 cycles, respectively.
Polysome-bound RNA preparation. Before harvest, cycloheximide (100 Ag/mL) was added to the medium for 3 min. The medium was then removed and the cells were washed with ice-cold PBS containing 100 Ag/mL cycloheximide. The cells were then scraped, centrifuged at 800 Â g for 5 min at 4jC, and cytoplasmic RNA was obtained by lysing the cell pellet in 1 mL of polysome buffer containing 10 mmol/L Tris-HCl (pH 8.0), 140 mmol/L NaCl, 1.5 mmol/L MgCl 2 , 0.5% NP40, and a RNase inhibitor, RNasin (500 units/mL; Promega). After the removal of nuclei, the cytosolic supernatant was supplemented with 100 Ag/mL cycloheximide, 665 Ag/mL heparin, 20 mmol/L DTT, and 1 mmol/L phenylmethanesulfonyl fluoride. Mitochondria and membrane debris were removed by centrifugation, and postmitochondrial supernatant was overlaid onto a 15% to 40% sucrose gradient (13) . Fractions (750 AL) were collected from the bottom of each gradient and deproteinated with 100 Ag of proteinase K in the presence of 1% SDS and 10 mmol/L EDTA. After acid phenol extraction, RNA integrity was controlled by electrophoresis analysis on 1.2% agarose gel. Densitometry (GelDoc, Bio-Rad) was used to determine fractions in which the 28S/18S ratio equals 2 (i.e., fractions corresponding to polysome-bound RNA). The polysome-bound RNA-containing fractions were pooled from each sucrose gradient according to the distribution profile.
Double-stranded cDNA and cRNA synthesis and microarray hybridization. Total RNA and polysomal RNAs were purified using the RNeasy mini-kit clean-up protocol (Qiagen). First-strand cDNA, doublestranded cDNA, and cRNA were synthesized, and cRNA was fragmented using Affymetrix kits and guidelines. 1 All cRNA final products were tested in terms of amount and integrity by Bioanalyzer (Agilent) before microarray hybridization. cRNA samples were processed on Affymetrix HGU133A arrays with strict adherence to the labeling, hybridization, and staining protocols provided by Affymetrix. GeneChip image analysis was done using GCOS v1.4 (Affymetrix). Probe-level analysis, preprocessing, and normalization steps were carried out using GeneTraffic 3.2.-11 (Iobion Stratagene Microarray Analysis Software).
Data mining. The Ingenuity Pathway Analysis 2 was used to analyze selected probe sets obtained from the microarray data. Each gene identifier was mapped to its corresponding gene object in the Ingenuity Pathways Knowledge Base. The application uses a right-sided Fisher's exact test to identify networks that had higher odds ratio of containing significant genes. These genes, called Focus Genes, were then overlaid onto a global molecular network. Networks of these Focus Genes were then algorithmically generated. For the selected probe sets listed in Supplementary Tables S1 and S2, the corresponding data from the Total RNA data sets were extracted. Scatter plots were then drawn and the corresponding correlation coefficients were calculated. Microarray data have been deposited into the Array Express repository 3 under the accession no. E-MEXP-958.
Results
Down-regulation of the Akt-mTOR pathway on hepatocytic differentiation. We investigated the Akt-mTOR pathway activity in the human HepaRG cells on their differentiation into hepatocyte-like cells. The amount of phosphorylated Akt (Ser 473 residue) decreased on differentiation, whereas total Akt amounts remained unchanged, indicative of a reduction in Akt activity on differentiation. Amounts of total and Ser 2448 -phosphorylated mTOR also decreased throughout the differentiation process (Fig. 1A) . Reduced phosphorylation of the mTOR substrates, 4E-BP1 and p70 S6 kinase, was also observed on differentiation (Fig. 1B) . In conclusion, the activity of the Akt-mTOR pathway decreases during differentiation of HepaRG cells into hepatocytelike cells.
Generation of HepaRG cells expressing a constitutively activated mTOR mutant and initial characterization. To determine the role of mTOR in hepatocytic differentiation and the consequence of its dysregulation, we generated HepaRG clones expressing a constitutively activated mTOR mutant (DTOR). mTOR contains a kinase domain and a repressor domain. The kinase activity of mTOR increases by 3.5-to 10-fold when the repressor domain is deleted (14) . DTOR-and backbone vector-bearing cells were generated and screened for the expression of the DTOR-AU1 tag fusion protein and of total mTOR ( Fig. 2A) . To confirm the functional activity of the transgene, 4E-BP1 phosphorylation was examined in proliferative and differentiated clones. Consistent with the induced enzymatic activity of DTOR, 4E-BP1 phosphorylation was higher in DTOR-bearing cells than in control cells at both the proliferative and differentiated states. In particular, 4E-BP1 remained in majority phosphorylated on differentiation in the DTOR-expressing cells (65 F 3%) whereas 4E-BP1 was only partially phosphorylated at the differentiated stage in control cells (39 F 2% for vector-bearing cells and 42 F 1% for HepaRG cells; Increased cell size is associated with tumorigenesis. The size of DTOR-expressing cells was significantly higher at days 5 and 7 postseeding, compared with vector-containing cells (day 5, P = 0.017; day 7, P = 0.035) and parental HepaRG cells (day 5, P = 0.018; day 7, P = 0.029; Fig. 2C ). At the seeding density used in this study, confluence is reached after 4 days. The cell size of DTOR-expressing cells was not significantly changed until day 7 and, therefore, DTOR cells, unlike control cells, did not seem to be sensitive to confluency. Cyclin D1 promotes mitogen-independent cell cycle progression in primary hepatocytes. To evaluate the capacity of DTOR-expressing cells to proliferate even at the end of the differentiation process, cyclin D1 mRNA expression levels were measured by semiquantitative reverse transcription-PCR (Fig. 2D) . Cyclin D1 mRNA levels were significantly higher in DTORexpressing cells compared with controls. Taken together, these data suggest that increased mTOR activity results in a proliferative advantage in HepaRG cells on differentiation.
Impaired hepatocytic differentiation in #TOR-expressing HepaRG cells and its reversion by rapamycin. The differentiation capability along the hepatocytic lineage was analyzed in DTOR-expressing cells. Whereas no morphologic differences were noticed between proliferative cell lines, striking differences were observed at the end of the differentiation process (Fig. 3A) . Differentiated hepatocytes display refractile cellular borders, dark cytosol, clearly delineated nuclei, and tridimensional polarization with the appearance of refringent circular canaliculi vertically. DTOR-expressing cells did not establish any structured monolayer in contrast to control cell lines, and none of the morphologic criteria described above was observed in DTOR cells in contrast to the two control cell lines. Bile canaliculi were counted in the three cell lines at the end of the differentiation process, indicating a quasi-absence of tridimensional polarization in DTOR-expressing cells [25 F 25/cm 2 in DTOR cells, 492 F 124/cm 2 in vectorcontaining cells (P = 0.021), and 342 F 51/cm 2 in HepaRG cells (P = 0.004); Fig. 3B ]. The capacity of hepatocytes to secrete plasmatic proteins in appropriate amounts correlates with their differentiation status. Levels of secreted a1-antitrypsin were measured in the three cell lines at the end of the differentiation protocol. The amount of a1-antitrypsin released in the supernatant by DTOR-expressing cells was 40.75 F 8% of the amount secreted by HepaRG cells, whereas the amount released by vectorbearing cells was 101 F 3% of the amount secreted by HepaRG cells (P < 0.001; Fig. 3C ).
To further confirm that impaired differentiation of DTORbearing HepaRG cells was indeed due to increased mTOR kinase activity and to exclude any clonal effect, differentiation of DTORexpressing HepaRG cells was carried out in the presence of an inhibitor of mTOR, rapamycin, in two independent experiments. Morphologic evaluation showed an organized and polarized phenotype in rapamycin-treated DTOR cells (Fig. 4A) , with a bile canaliculi density comparable to levels found in control cell lines [693 F 233/cm 2 in rapamycin-treated DTOR cells and 50 F 10/ cm 2 in vehicle-treated DTOR cells (P = 0.05); Fig. 4B ; see also Fig. 3B ]. In conclusion, increased mTOR activity impairs the morphologic and biochemical hepatocytic differentiation of the HepaRG cells.
Loss of TGF-B responsiveness in #TOR-expressing HepaRG cells. TGF-h plays a critical role in the transition of stem cells or progenitor cells to a fully differentiated phenotype in the liver parenchyma and controls cell growth and apoptosis in the liver. Active TGF-h1 secretion levels were assessed in the DTORcontaining HepaRG cells and in control cells. Similar amounts of this cytokine (<70 pg/mL/d) were detected in the supernatant of all cell lines, independently of DTOR expression (data not shown). In comparison, conventional doses of TGF-h used in in vitro assays are between 2,000 and 5,000 pg/mL. Therefore, the capability of DTOR to modulate the antiproliferative effects of TGF-h1 was tested. No apoptosis was observed in any cell line on TGF-h1 treatment (data not shown). Phase-contrast microscopy analysis indicated that DTOR-expressing HepaRG cells were less susceptible to the acquisition of a spindle-shaped morphology, typical of TGF-h1-induced response (Fig. 5A ). In addition, DTORexpressing cells were resistant to the antiproliferative effect of TGF-h1 compared with control cells with a proliferation inhibition rate of 9 F 2% in DTOR-expressing cells, 51 F 9% in vector-containing cells (P = 0.043), and 38 F 15% in HepaRG cells (P = 0.003; Fig. 5B ). Finally, expression of the cell cycle inhibitor p21 (WAF1/CIP1) was induced on TGF-h1 treatment in control cell lines but not in DTOR-expressing cells (Fig. 5C ). Taken together, these results suggest that increased mTOR activity leads to loss of TGF-h responsiveness in hepatocytes.
Comparative polysome-bound RNA profiling of #TOR-expressing HepaRG cells and control cell lines on hepatocytic differentiation and data mining. To identify the mechanisms by which activated mTOR impairs hepatocytic differentiation and generates a preneoplastic phenotype in the HepaRG cells, profiling of total RNAs and polysome-bound RNAs was done in DTORexpressing cells and in control cells (vector-bearing and parental HepaRG) at the proliferative stage and at the end of the differentiation protocol using Affymetrix microarrays. mTOR is a Figure 1 . Down-regulation of the Akt/mTOR pathway on hepatocytic differentiation. Differentiation of HepaRG cells was induced as described in Materials and Methods. Expression levels of phospho-Akt (P-Akt ), Akt, phospho-mTOR (P-mTOR ), and mTOR (A) and of phospho-4E-BP1 (P-4E-BP1 ), 4E-BP1, phospho-p70 S6 kinase (P-p70S6k ), and p70 S6 kinase (B ) were assessed by immunoblotting. regulator of translation and, therefore, we used polysome-bound RNA profiling for our analysis to detect changes occurring at both transcriptional and translational levels. We selected polysomebound transcripts significantly modified in control cells by at least 2-fold on differentiation in three independent experiments but not in DTOR cells (P V 0.05). These include 590 up-regulated (Supplementary Table S1 ) and 49 down-regulated (Supplementary  Table S2 ) transcripts.
To investigate whether activation of mTOR was affecting transcripts regulated at the transcriptional level or at posttranscriptional levels on differentiation of control cells, total RNA fold changes in control cells were plotted against polysome-bound RNA fold changes in control cells for these selected transcripts. For the up-regulated transcripts, the slope of the regression curve calculated from all experimental values was 0.6222 (Fig. 6A) . The slope of this curve is greater than zero, indicative of a positive correlation between polysome-bound RNA and total RNA fold change values. However, the correlation coefficient for this regression curve was 0.3798, showing a poor correlation between changes in the polysome-bound fractions and changes in total RNA on differentiation of HepaRG cells. Similarly, a poor correlation between changes in the polysome-bound fractions and changes in total RNA on differentiation of HepaRG cells was observed for the down-regulated genes, with a correlation coefficient of 0.0791 (Fig. 6B) . These results suggest that mTOR activity is specifically targeting transcripts modified at a posttranscriptional level on hepatocytic differentiation of HepaRG cells. Tables S1 and S2 were analyzed using the Ingenuity Systems Pathways Knowledge Base 4 (March 2006 release). This database enables search for gene product interactions and annotations coming from curated data from publications and peer-reviewed resources. The Ingenuity pathway analysis identified two molecular networks generated from the up-regulated transcripts displaying 100% overlay between the selected regulated genes found in our study and the software-preselected members. The first network includes 35 genes associated with the proapoptotic tumor necrosis factor (TNF) superfamily-and caspase-related pathways and with the IFN system (Fig. 6C) . It includes two members of the TNF superfamily, TNFSF10 [TNF-related apoptosis-inducing ligand (TRAIL)] and TNFSF13 (APRIL), and six members of the TNF receptor superfamily, TNFRSF1A, TNFRSF10C (TRAILR3 ), TNFRSF25 (death receptor 3, Apo3), TNFRSF5 (CD40), TNFRSF6B (decoy receptor 3), and TNFRSF11B. The other main components of this network are caspase-8 (CASP8) and caspase-9 (CASP9), Janus kinase 2 (JAK2), and signal transducer and activator of transcription 1 (STAT1). Other proteins associated with increased susceptibility to apoptosis include CRADD, FADD, TRADD, MADD, IHPK2, sphingomyelin phosphodiesterase 1, and programmed cell death 8. Finally, two members of this network are IFN-inducible genes: 2 ¶,5 ¶-oligoadenylate synthetase-1 (OAS1) and IFI16. IFI16 showed the largest fold change (54.1-fold) and is also associated with proapoptotic functions, in addition to negative regulator of cell growth. In addition to the transcripts depicted in this network, several transcripts also involved in susceptibility to apoptosis included cell death activator CIDE-3, insulin-like growth factor (IGF)-binding protein 1, tuberous sclerosis complex protein 2, growth arrest-specific 2, and programmed cell death 4 (Table S1 ).
The contents of the Supplementary
The second network is associated with lipid and carbohydrate metabolisms and includes 35 genes (Fig. 6D) . These include the peroxisome proliferator-activated receptors a and y (PPARa and PPARy) and the retinoid X receptor h (RXRh), a modulator of PPARa activity. PPARs and RXRs induce the expression of proteins and enzymes involved in pyruvate metabolism, such as PDK2, PDK3, PDK4, and PDHA1, and in lipid metabolism such as HADHA, HADHB, C/EBPy, ACOX1, and FABP4. In addition to the transcripts depicted in this network, transcripts involved in lipid transport and/or metabolism included CCAAT/enhancer binding protein (C/EBP)-a, solute carrier family 27-member 3, sterol regulatory element-binding transcription factor 2, lipoic acid synthetase, low-density lipoprotein receptor-related protein 1, and apolipoprotein M (Table S1) .
Remarkably, down-regulation of the growth factors vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), fibroblast growth factors 2 and 5 (FGF2 and FGF5), and PDGFB upon differentiation of the HepaRG cells was inhibited by DTOR (Table S2) .
Taken together, these results indicate that DTOR affects the posttranscriptional regulation of genes vital for modulating sensitivity to apoptosis, lipid homeostasis, and hepatocellular growth.
Discussion
In this study, we used the human HepaRG cell line to increase our knowledge about the possible involvement of mTOR activation (10) . The number of human liver progenitor cells correlates with the severity of liver diseases such as chronic viral hepatitis, alcoholic and nonalcoholic fatty liver diseases, which predispose patients to HCC. Activation of progenitor cells in these diseases suggests that they form a potential target cell population, precursors of HCC, and, indeed, a subtype of human HCCs express one or more markers of progenitor cells (15, 16) .
We showed that the activity of mTOR decreases on hepatocytic differentiation of the HepaRG cells and that sustained mTOR activation impairs their differentiation and their polarization status. DTOR-expressing cells were unable to settle tridimensional organization and polarization, mandatory for normal endocrine and exocrine functionality of the hepatocyte. In agreement with our observation that control HepaRG cells but not DTOR-expressing cells reached a mature hepatocytic functional state, induction of radixin and catenin-y1, genes involved in epithelium polarization and organization (17) , was impaired by mTOR activation. Loss of hepatocytic and trabecular organization in the lobule is a hallmark of many HCCs and HCC grades have been defined according to these features (18) . Another hallmark of many HCCs is their loss of responsiveness to TGF-h1. TGF-h1 has antiproliferative and proapoptotic properties in normal hepatocytes and in rat partial hepatectomy models. In our study, DTOR expression conferred resistance to TGF-h1-induced inhibition of proliferation. Recent studies suggested that mTOR abolishes TGF-h/ALK5-mediated Smad3 activation (19) , in agreement with our observed antagonism between the Akt/mTOR pathway and TGF-h1 antitumorigenic function.
mTOR is a critical component of translational control (7) . To identify the altered events in DTOR-expressing HepaRG cells leading to their preneoplastic phenotype, we analyzed polysomebound RNAs by microarray and selected changes occurring on differentiation in control cells but not in DTOR cells. Comparing changes of the selected transcripts at both the total RNA and polysome-bound RNA levels indicated that mTOR specifically targeted genes posttranscriptionally regulated on differentiation of HepaRG cells. mTOR impaired the up-regulation of a large number of members of the TNF/caspase transduction pathway. These include TNFSF10 (TRAIL) and caspase-8, known to play a crucial role in inducing apoptosis in human hepatocytes and HCCs (20) . Caspase-8, a key mediator of death receptor-induced apoptosis, has previously been reported to be frequently inactivated by epigenetic silencing in many tumors. This network also shows that mTOR impaired the up-regulation of JAK2 and STAT1 and of IFN-induced proteins such as OAS1 or IFI16 (>50-fold). There is currently no information on IFI16 in the liver but IFI16 is an essential mediator of growth inhibition in medullary thyroid carcinoma cells (21) and of p53 and p21 (WAF1/CIP1) functions (22) . IFI16 expression is increased by TRAIL in breast carcinoma cells (23) . Noteworthy, both up-regulated caspases identified (caspase-8 and caspase-9) belong to the initiator caspases family, whereas none of the members of the effector caspase family (caspase-3, caspase-6, and caspase-7; ref. 24 ) was affected, supporting the fact that control cells did not undergo apoptosis in culture. Numerous additional transcripts coding for antiproliferative, neoplastic transformation inhibitors and proapoptotic proteins were identified to be up-regulated in control cells on differentiation but not in DTOR-expressing cells. Normal hepatocytes are highly sensitive to cell death upon, for example, Figure 5 . Loss of TGF-h responsiveness in DTOR-expressing HepaRG cells. Cells were incubated with TGF-h1 for 3 d. A, pictures were taken from three randomly selected fields. B, cells were analyzed by fluorescence-activated cell sorting using the cell count function of the device. Columns, mean of three experiments; bars, SD. C, p21 (WAF1/CIP1) expression levels were assessed by immunoblotting. Figure 6 . Correlation between total RNA and polysomal RNA fold changes and Ingenuity pathway analysis. Scatter plots were drawn for the selected 615 up-regulated probe sets (A) and the selected 49 down-regulated probe sets (B) between the log-transformed polysome-bound RNA fold changes and the corresponding total RNA fold changes. Dotted line, total/polysome-bound RNA ratio of 1 (slope = 1). Solid line, regression curve calculated from all plots. C and D, the identified networks are represented as nodes displayed using various shapes that represent the functional class of the gene product and lines/arrows displayed with various labels that describe the specific relationship between the nodes. Gene abbreviation is located within the symbol. The significance of the shapes of the symbols, and the letters mentioned between nodes can be found in the Ingenuity website (http://www.ingenuity.com). Solid lines, direct interaction. Dotted lines, indirect interaction. An asterisk appears next to any gene for which the input file contained more than one identifier. C, a total of 35 differentially expressed genes were revealed in this network with a highly significant score of 50. Gene symbols found in this network: ADM, adrenomedullin; CASP8, caspase-8, apoptosis-related cysteine protease; CASP9, caspase-9, apoptosis-related cysteine protease; TNFRSF5, TNF receptor superfamily, member 5 or CD40; CRADD, CASP2 and RIPK1 domain containing adaptor with death domain; CTNND1, catenin (cadherin-associated protein), y1; DHFR, dihydrofolate reductase; ENO1, enolase 1, (a); FADD, Fas (TNFRSF6)-associated via death domain; FAF1, Fas (TNFRSF6)-associated factor 1; IFI16, IFN, g-inducible protein 16; IHPK2, inositol hexaphosphate kinase 2; JAK2, Janus kinase 2; MADD, mitogen-activated protein kinase activating death domain; OAS1, 2 ¶,5 ¶-oligoadenylate synthetase 1; PDCD8, programmed cell death 8; PDE4A, phosphodiesterase 4A, cyclic AMP-specific; PECAM1, platelet/endothelial cell adhesion molecule; PIAS1, protein inhibitor of activated STAT, 1; PIP5A1C, phosphatidylinositol-4-phosphate 5-kinase, type I, g; PTBP1, polypyrimidine tract-binding protein 1; PTPN6, protein tyrosine phosphatase, nonreceptor type 6; RBM5, RNA-binding motif protein 5; SMPD1, sphingomyelin phosphodiesterase 1, acid lysosomal; SRPX, sushi-repeat-containing protein, X-linked; STAT1, signal transducer and activator of transcription 1; TCEB2, transcription elongation factor B (SIII), polypeptide 2; TNFRSF25, TNF receptor superfamily, member 25; TNFRSF10C, TNF receptor superfamily, member 10c, decoy; TNFRSF11B, TNF receptor superfamily, member 11b; TNFRSF1A, TNF receptor superfamily, member 1A; TNFRSF6B, TNF receptor superfamily, member 6b, decoy; TNFSF10, TNF (ligand) superfamily, member 10 (TRAIL); TNFSF13, TNF (ligand) superfamily, member 13 (APRIL); TRADD, TNFRSF1A-associated via death domain. D, a total of 35 differentially expressed genes were revealed in this network with a highly significant score of 50. Gene symbols found in this network: ACOX1, acyl-CoA oxidase 1; AKAP13, a kinase (PRKA) anchor protein 13; ARNT, aryl hydrocarbon receptor nuclear translocator; C19ORF29, chromosome 19 open reading frame 29; CEBPD, CCAAT/enhancer binding protein, y; CITED2, CREB binding protein/p300-interacting transactivator, 2; CPT2, carnitine palmitoyltransferase II; DDIT4, DNA-damage-inducible transcript 4; EFNA1, ephrin-A1; FABP4, fatty acid-binding protein 4; FGB, fibrinogen h chain; FKBP1A, FK506 binding protein 1A; FN1, fibronectin 1; FRAP1, FK506 binding protein 12-rapamycin associated protein 1; GLUD1, glutamate dehydrogenase 1; GPHN, gephyrin; HADHA, hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase, a subunit; HADHB, hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase, h subunit; IL1R1, interleukin-1 receptor, type I; MIA, melanoma inhibitory activity; MLYCD, malonyl-CoA decarboxylase; NAB2, nuclear polyadenylated RNA-binding protein; PDHA1, pyruvate dehydrogenase (lipoamide) a1; PDK2, pyruvate dehydrogenase kinase, isoenzyme 2; PDK3, pyruvate dehydrogenase kinase, isoenzyme 3; PDK4, pyruvate dehydrogenase kinase, isoenzyme 4; PPARA, peroxisome proliferator-activated receptor, a; PPARD, peroxisome proliferator-activated receptor, y; PRKAR1A, protein kinase, cyclic AMP-dependent, regulatory, type I, a; PRKAR2A, protein kinase, cyclic AMP-dependent, regulatory, type II, a; RHEB, Ras homologue enriched in brain; RXRB, retinoid X receptor h; ST6GAL1, ST6 h-galactosamide a-2,6-sialyltranferase 1; TCF4, transcription factor 4; TSC2, tuberous sclerosis 2.
drug-induced liver toxicity, and three-dimensional polarization sensitizes hepatocytes to Fas apoptotic signaling (25) . Therefore, sustained activation of mTOR may contribute to neoplastic cell expansion by altering receptor-induced apoptosis sensitivity. Our data also suggest an important molecular cross-talk between the TRAIL and IFN pathways in liver progenitor cells. mTOR may induce resistance to TRAIL-and/or IFN-induced apoptosis. Defects in IFN signaling that result in loss of expression of IFNinducible proteins are associated with cellular immortalization, an important early event in the development of human cancer.
mTOR activation impaired the induction of the transcription factors PPARa, PPARy, and RXRh and their target genes. The lipid-lowering function of PPARa occurs across a number of mammalian species, thus showing the essential role of this nuclear receptor in lipid homeostasis and normal liver function. Mice deficient in PPARa lack hepatic peroxisomal proliferation, have an impaired expression of several hepatic target genes, and show a massive accumulation of lipids in their livers (26) . Ethanol impairs fatty acid catabolism in liver by blocking PPARamediated responses contributing to the development of alcoholic fatty liver, which can be overcome by PPARa agonists (27) . HCV infection is also associated with altered expression and function of PPARa (28) . PPARy also plays a role in lipid metabolism including cholesterol efflux and fatty acid oxidation (29, 30) ; activates fat metabolism to prevent obesity (31); and regulates fatty acid synthesis, glucose metabolism, and insulin sensitivity (32) . Interestingly, it has been reported that PPARy attenuates colon carcinogenesis (33) . RXR heterodimers serve as key regulators in cholesterol homeostasis by governing reverse cholesterol transport from peripheral tissues, bile acid synthesis in liver, and cholesterol absorption in intestine (34) . Liver-specific loss of function of retinoic acid leads to steatohepatitis and liver tumors in vivo (35) . Therefore, sustained mTOR activity may contribute to the development of steatosis observed in most HCCs by impairing lipid homeostasis.
Another major target of DTOR is C/EBPa. This transcription factor regulates two aspects of hepatic terminal differentiation: induction of differentiation-specific genes and repression of mitogenesis (36) (37) (38) . C/EBPa reduces HCC susceptibility in mice (39) and down-regulation of C/EBPa in HCC correlates with tumor size and progression (40) . C/EBPa-deficient mice present with severely disturbed liver architecture with acinar formation in a pattern suggestive of either regenerating liver or HCC, abnormally active hepatocytic proliferation, impaired hepatic glycogen storage, and accumulation of lipids in the liver (41, 42) . These mice also show lowered plasma levels of free fatty acid, triglyceride, and cholesterol as well as marked changes in PPARa and apoliproteins (43) . Therefore, by impairing induction of C/EBPa on hepatocytic differentiation, mTOR is affecting numerous vital liver-specific functions.
Dysregulation of pleiotropic growth factors and their receptors represent a central protumorigenic principle in human hepatocarcinogenesis. Especially the IGF, HGF, and TGF-h pathways, all found affected by activated mTOR in the HepaRG cells, contribute to proliferation, antiapoptosis, and invasive behavior of tumor cells. HGF is the primary agent promoting the proliferation and apoptosis resistance of mature hepatocytes. Serum HGF levels are strongly associated with liver diseases including insulin resistance and nonalcoholic steatohepatitis. Blockage of HGF suppresses HCC in mice by inhibiting tumor cell motility and angiogenesis (44) . FGF2, VEGF, and PDGFB are potent mitogenic and angiogenic factors and stimulate tumor growth (45) . Expression of VEGF and FGF2 is altered in patients with HCC and, interestingly, VEGF and FGF2 concentrations are elevated before the emergence of HCC (46) . By maintaining high levels of expression of these factors on hepatocytic differentiation, mTOR may accelerate abnormal proliferation and angiogenesis.
In conclusion, we have shown that an enhanced activity of mTOR, as found in clinical HCC samples, is capable of preventing hepatocytic differentiation not only through inhibition of induction of C/EBPa but also by preventing hepatocytic polarization. In addition, sustained mTOR activity may lead to reduced susceptibility to TGF-h antiproliferative effects and to TRAIL/TNF-and IFN-induced apoptosis. Sustained mTOR activity may also lead to abnormal expression of genes modulating lipid homeostasis, hepatocellular growth, and angiogenesis. These effects, taken together, could contribute to the neoplastic transformation of these cells. Our study also suggests that combination therapy strategies aimed at overcoming TRAIL and IFN resistance and PPARa and PPARy defects may be effective for treatment of HCC with activated mTOR or PTEN deletion.
